BYSI compared with AARD: revenue, margins and what each company keeps, and the suppliers and customers both name

BYSIBeyondSpring Inc.

Mkt capRevenueRevenue

AARDAardvark Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

BYSIBeyondSpring Inc.

AARDAardvark Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BYSI1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−15.21%—

AARD

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±54.2%▼−8.62%×0.16

May 7 '26±56.7%▼−4.92%×0.09

= impliedBYSI realized, solidAARD realized, hatchedOne scale, both sides: full bar = 90%× = |realized| ÷ impliedSource: market data

Q1 FY26

±89.9%

▼−7.26%

×0.08

Q3 FY25—▼−8.66%—

BYSIBeyondSpring Inc.

0.79· pre 0.84· delayed

Mkt cap$33.1M

AARDAardvark Therapeutics, Inc.

1.24· pre 1.22· delayed

Pre-marketNov 3 '26delayed

Mkt cap$29.7M

Compare

Pre-marketNov 3 '26delayed

BYSIBeyondSpring Inc.

AARDAardvark Therapeutics, Inc.

0.79pre 0.84delayed

Price

1.24pre 1.22delayed

$33.1M

Mkt cap

$29.7M

BYSI0.79vsAARD1.24Pre-marketNov 3 '26delayed